This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed the most recent trading day at $22.46, moving +1.26% from the previous trading session.
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed the most recent trading day at $20.90, moving +0.87% from the previous trading session.
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Meridian Bioscience (VIVO) closed at $20.88, marking a +1.11% move from the previous day.
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed at $20.45 in the latest trading session, marking a +6.68% move from the prior day.
Meridian Bioscience (VIVO) Beats Q2 Earnings Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 16.67% and -2.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience (VIVO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed at $20.76 in the latest trading session, marking a -1.66% move from the prior day.
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed at $22.43 in the latest trading session, marking a +1.72% move from the prior day.
Meridian Bioscience (VIVO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed the most recent trading day at $23.94, moving -1.4% from the previous trading session.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience
4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
Has Meridian Bioscience (VIVO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VIVO) Outperforming Other Medical Stocks This Year?
Here's Why You Should Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.
Abbott (ABT) Nutrition Shows Robust Momentum Amid Pandemic
by Zacks Equity Research
Within Medical Device, Abbott (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Cardiovascular Systems' (CSII) New Buyout Boosts CAD/PAD Line
by Zacks Equity Research
Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.
Meridian Bioscience, Gold Fields, Steel Dynamics, Toll Brothers and Owens Corning highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Meridian Bioscience, Gold Fields, Steel Dynamics, Toll Brothers and Owens Corning highlighted as Zacks Bull and Bear of the Day
Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Delay in FDA approval for latest COVID test hasn't altered growth or value at 3X sales
NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.
Penumbra (PEN) Launches INDIGO System Lightning 7 in US
by Zacks Equity Research
Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.
Encompass Health (EHC) Continues to Expand Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) plans to construct a hospital in Texas for offering improved rehabilitative services, which highlights its efforts to bolster presence in the state.
Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient
by Zacks Equity Research
Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.
Zacks.com featured highlights include: Crocs, MEDIFAST, Sprouts Farmers Market, Meridian Bioscience and iRobot
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, MEDIFAST, Sprouts Farmers Market, Meridian Bioscience and iRobot
5 Must-Buy Efficient Stocks to Make Your Portfolio Stand Out
by Tirthankar Chakraborty
Crocs (CROX), iRobot (IRBT), Sprouts Farmers Market (SFM), Meridian Bioscience (VIVO) & MEDIFAST (MED) are the top five companies boasting solid efficiency levels at present.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.